AI summary by TwinMind
China's Vaccine Diplomacy
Wendover Productions
17m 47s
China's Early Pandemic Response and Image Recovery Efforts
- Spring 2020: China emerged triumphant from COVID lockdown while rest of world entering pandemic
- Focused on recovering from global image hit due to perceived early virus mismanagement
- Attempted to be viewed as country that crushed COVID domestically and led global fight
- Supplied ventilators to JFK airport, medical supplies via national airlines, test kits globally
- Positioned itself at center of global virus fight
Quality Issues with Chinese Medical Supplies
- Donations turned to purchases, revealing major quality problems
- 90% of mask certifications from China were fake according to one measure
- Tests supposed to have 80% sensitivity actually had 30%
- Chinese officials demanded public displays of thanks for donations
- Reinforced "Chinese-made as inferior" narrative
- Diplomacy effort potentially further damaged global image
Chinese Vaccine Development Timeline
- Multiple private companies, state-owned enterprises, government institutes began vaccine work
- Spring 2020: Strong viable candidates emerged
- March 17, 2020: First Chinese vaccine (Ad5-nCoV by CanSino Biologics) entered Phase 1 trial
- 108 adults in Wuhan received shots
- April 11: Became first vaccine worldwide to enter Phase 2 trials (508 participants)
- July 20: Results showed vaccine was safe and generated desired immune response
Phase 3 Trial Challenges
- Phase 3 trials test real-world effectiveness by comparing vaccine vs. placebo groups
- Problem: China's daily COVID cases reduced to double-digit levels by late summer
- In country of 1+ billion, most Phase 3 trials have <50,000 participants
- Would take years/decades at those caseloads to get hundreds of infections needed
- Impossible to complete COVID vaccines in China due to successful virus suppression
International Phase 3 Trials and Diplomatic Arrangements
- CanSino Ad5-nCoV vaccine started Phase 3 trials in Russia, Pakistan, Saudi Arabia, Mexico, Argentina, Chile
- Other candidates moved to dozens of countries with severe COVID epidemics
- China had to curry favor with each government
- Typically offered priority access to vaccines being tested in exchange for trial hosting
Chinese Vaccine Approval and Deployment
- Five Chinese-made vaccines approved in country
- Widespread criticism of development practices:
- Started vaccinating public before Phase 3 trials reached endpoints
- Not forthcoming with clinical trial data
- Misrepresented efficacy ratings
- December 30: BBIBP-CorV vaccine by Sinopharm approved, one of first COVID vaccines deployed globally
- Despite evidence vaccines are acceptably safe/effective, potentially less so than other approved vaccines
Global Vaccine Distribution Strategy
- Despite 1.4 billion people to inoculate, first doses sent beyond borders
- Sinopharm has orders from 100+ countries (details not publicly known)
- Goal: succeed where masks/ventilators/tests failed in 2020
- Western vaccines (Moderna/Pfizer): 95% efficacy vs. Chinese vaccines: 50-83%
- Western vaccines have order obligations into 2022, Chinese vaccines more available
- Countries choosing less effective vaccine sooner vs. waiting for better alternatives
Vaccine Diplomacy and Free Distribution
- Major diplomacy coup: historically Western-allied countries (Hungary, Mexico) turning to China
- Free vaccine distributions:
- Mongolia, Sri Lanka: 300,000 doses
- Algeria, Sierra Leone, Zimbabwe: 200,000 doses
- Belarus, Equatorial Guinea, Gabon, Mozambique, Namibia, Bolivia: 100,000 doses
- Amounts sufficient for healthcare worker vaccination news clips
- Demonstrates safety/effectiveness, encouraging larger orders
Diplomatic Influence and Taiwan Relations
- State-owned enterprise distribution raises questions about diplomatic-based allocation
- Algeria example: Chinese official noted 50-year-old UN vote switching recognition from Taiwan to PRC
- Mentioned Algeria's Belt and Road Initiative participation before announcing 200,000 vaccine donation
- South America: 10 of 12 countries vaccinated with Chinese vaccines
- Only exceptions: Suriname (lowest population) and Paraguay
- Paraguay recognizes Taiwan as independent nation
- Zero overlap between countries recognizing Taiwan and those receiving Chinese vaccines
Brazil-Huawei-Vaccine Connection
- Brazil-US relations strong under Bolsonaro/Trump
- Brazil banned Huawei from 5G network following US lead
- February: Brazilian communications minister Fabio Faria visited Beijing, met Huawei executives
- Faria "took advantage of trip to ask for vaccines"
- Chinese ambassador letter emphasized cooperation importance
- Weeks later: Brazil changed 5G auction rules to allow Huawei participation
- Huawei didn't deny tit-for-tat deal, said they could "facilitate communication" between governments
Manufacturing Challenges and Domestic Vaccination Lag
- mRNA vaccines (Moderna/Pfizer) relatively easy to manufacture
- Chinese vaccines use attenuated/dead virus or portions - time-consuming, harder to scale
- mRNA vaccines include genetic instructions for spike protein creation
- Chinese vaccine production slower due to:
- Slow manufacturing process
- Priority obligations to trial hosting countries
- Robust vaccine diplomacy program
- Insistence on Chinese-made vaccines only
Domestic Vaccination Statistics (as of March)
- China: 5 doses per 100 citizens
- EU countries: 10-15 per 100
- US: 35 per 100
- UK: 42 per 100
- Estimates: China will achieve widespread vaccination end of 2022
- Same timeframe as India, Iran, Egypt, Ethiopia, Colombia
- Western world expected back to normal at least a year earlier
Strategic Implications and Image Concerns
- China's goal: be viewed as equal to US/Europe superpower status
- Risk of prolonged border restrictions, lockdowns, economic uncertainty
- Domestic and international questions about prioritizing foreign distribution
- Questions about not purchasing more effective foreign vaccines
- Potential narrative control loss affecting foreign and domestic image
- Risk of suffering in COVID-19's "third and final act"
